NCT06641544View on ClinicalTrials.gov

The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer

PHASE4RecruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

October 17, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Inetetamab

Group A received Inetetamab+Pertuzumab+TPC, while Group B received Inetetamab+Pyrotinib+TPC.

Trial Locations (1)

516621

RECRUITING

Sun Yat sen Memorial Hospital of Sun Yat sen University Shenzhen Shantou Central Hospital, Shanwei

All Listed Sponsors

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

NCT06641544 - The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter